HomeACADEMIA
ACADEMIA

New Treatment GL for Advanced HCC to Be Issued in October, Will Recommend Nexavar for 1st-Line Treatment
(Jul.11.2017)

The Japan Society of Hepatology (JSH) has drafted “clinical practice guidelines for hepatocellular carcinoma 2017”, which it plans to issue in mid-October. This is the first revision of the guidelines in four years. They will strongly recommend Bayer Yakuhin’s Nexavar (sorafenib) as a first-line treatment for unresectable, advanced hepatocellular carcinoma (HCC) ...
(LOG IN FOR FULL STORY)

News Calendar